Limits...
Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.

Woo T, Okudela K, Mitsui H, Tajiri M, Rino Y, Ohashi K, Masuda M - PLoS ONE (2015)

Bottom Line: The aim of the present study was to elucidate the potential molecular basis of these highly malignant lung tumors by focusing on S100 proteins (S100A2, S100A7, and S100A11), which are downstream targets of oncogenic KRAS and promoters of tumor progression.Furthermore, higher levels of S100A11 were associated with shorter disease-free survival.These results suggest that the up-regulation of S100A11 plays a role in tumor progression, particularly in KRAS-mutated lung adenocarcinomas.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.

ABSTRACT
We previously reported that patients with lung adenocarcinomas with KRAS gene mutations and strong proliferating activity had poorer outcomes, even in the early stage of the disease. The aim of the present study was to elucidate the potential molecular basis of these highly malignant lung tumors by focusing on S100 proteins (S100A2, S100A7, and S100A11), which are downstream targets of oncogenic KRAS and promoters of tumor progression. The immunohistochemical expression of S100 proteins was examined in 179 primary lung adenocarcinomas, and the potential relationships between their levels and clinicopathologic factors were analyzed. Among the three subtypes, S100A11 levels were significantly higher in adenocarcinomas with KRAS mutations and strong proliferating activity. They were also higher in adenocarcinomas with poorly differentiated tumors. Furthermore, higher levels of S100A11 were associated with shorter disease-free survival. These results suggest that the up-regulation of S100A11 plays a role in tumor progression, particularly in KRAS-mutated lung adenocarcinomas.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier Disease-free survival curves by S100A11 expression levels for stage I lung adenocarcinomas.Five-year disease-free survival rates were 76.3% in high-S100A11 expressers (n = 61) and 90.1% in low-S100A11 expressers (n = 118). The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4636248&req=5

pone.0142642.g004: Kaplan-Meier Disease-free survival curves by S100A11 expression levels for stage I lung adenocarcinomas.Five-year disease-free survival rates were 76.3% in high-S100A11 expressers (n = 61) and 90.1% in low-S100A11 expressers (n = 118). The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test).

Mentions: Since the results obtained suggested that the up-regulation of S100A11 was involved in tumor progression, particularly in KRAS-mutated lung adenocarcinomas, its prognostic value was subsequently verified. One hundred and seventy-nine patients with lung adenocarcinomas at stage I were examined. S100A11 expression scores of <1.65 and > = 1.65 were classified as low and high based on a receiver operating characteristic curve (area under the curve 0.629, 95% confidential interval 0,501–0.757). One hundred and eighteen patients were low-expressers, while 61 were high-expressers. Five-year disease-free survival rates were 90.1% and 76.3% in low- and high-S100A11 expressers, respectively. The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test, Fig 4). On the other hand, a correlation was not found between S100A11 expression levels and the site of recurrent disease (data not shown).


Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.

Woo T, Okudela K, Mitsui H, Tajiri M, Rino Y, Ohashi K, Masuda M - PLoS ONE (2015)

Kaplan-Meier Disease-free survival curves by S100A11 expression levels for stage I lung adenocarcinomas.Five-year disease-free survival rates were 76.3% in high-S100A11 expressers (n = 61) and 90.1% in low-S100A11 expressers (n = 118). The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4636248&req=5

pone.0142642.g004: Kaplan-Meier Disease-free survival curves by S100A11 expression levels for stage I lung adenocarcinomas.Five-year disease-free survival rates were 76.3% in high-S100A11 expressers (n = 61) and 90.1% in low-S100A11 expressers (n = 118). The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test).
Mentions: Since the results obtained suggested that the up-regulation of S100A11 was involved in tumor progression, particularly in KRAS-mutated lung adenocarcinomas, its prognostic value was subsequently verified. One hundred and seventy-nine patients with lung adenocarcinomas at stage I were examined. S100A11 expression scores of <1.65 and > = 1.65 were classified as low and high based on a receiver operating characteristic curve (area under the curve 0.629, 95% confidential interval 0,501–0.757). One hundred and eighteen patients were low-expressers, while 61 were high-expressers. Five-year disease-free survival rates were 90.1% and 76.3% in low- and high-S100A11 expressers, respectively. The strong expression of S100A11 correlated with shorter disease-free survival in post-operative lung adenocarcinomas (p = 0.0182 in the Log-rank test, Fig 4). On the other hand, a correlation was not found between S100A11 expression levels and the site of recurrent disease (data not shown).

Bottom Line: The aim of the present study was to elucidate the potential molecular basis of these highly malignant lung tumors by focusing on S100 proteins (S100A2, S100A7, and S100A11), which are downstream targets of oncogenic KRAS and promoters of tumor progression.Furthermore, higher levels of S100A11 were associated with shorter disease-free survival.These results suggest that the up-regulation of S100A11 plays a role in tumor progression, particularly in KRAS-mutated lung adenocarcinomas.

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.

ABSTRACT
We previously reported that patients with lung adenocarcinomas with KRAS gene mutations and strong proliferating activity had poorer outcomes, even in the early stage of the disease. The aim of the present study was to elucidate the potential molecular basis of these highly malignant lung tumors by focusing on S100 proteins (S100A2, S100A7, and S100A11), which are downstream targets of oncogenic KRAS and promoters of tumor progression. The immunohistochemical expression of S100 proteins was examined in 179 primary lung adenocarcinomas, and the potential relationships between their levels and clinicopathologic factors were analyzed. Among the three subtypes, S100A11 levels were significantly higher in adenocarcinomas with KRAS mutations and strong proliferating activity. They were also higher in adenocarcinomas with poorly differentiated tumors. Furthermore, higher levels of S100A11 were associated with shorter disease-free survival. These results suggest that the up-regulation of S100A11 plays a role in tumor progression, particularly in KRAS-mutated lung adenocarcinomas.

No MeSH data available.


Related in: MedlinePlus